SecBot SecBot

CTKB

Cytek Biosciences, Inc.
Nasdaq· Laboratory Analytical Instruments· Inc. DE· CIK 0001831915 Biotech & Drug Discovery
$5.98 +0.09 (+1.53%)
Oct 27 4:00 PM ET · prev $5.89
Market cap
$726.6M
Small cap
Median target
$6.00
+0% · range $5.00–7.50
Next earnings
Nov 4
in 8 days
1 year
+42.4%
from $4.20 · Oct 28
30 days
+4.2%
from $5.74
52-week range
$3.36–6.09
−2% from high · low May 14
Avg volume 20D
1.36M
Oct 9 spike 3.88M
Short interest
4.41M
≈3.4% of shares · −15.4%
Days to cover
2.7
at average volume
Insider net
$0
no open-market trades · since May 18
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 4, 2026
Strongest BEARISH Cytek disclosed a jury verdict in a patent infringement case brought by Beckman Coulter. The jury found in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since May 18. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 20 added (0 new), 20 trimmed or exited.

  • Short sellersCOVERING

    Short interest −15.4% to 4.41M shares. 2.7 days to cover, ≈3.4% of shares.

  • TrendUPTREND

    15% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.TRIM9,578,643$42.4M
MILLENNIUM MANAGEMENT LLCADD9,338,010$41.4M
Boston PartnersADD7,660,943$33.9M
STATE STREET CORPTRIM2,566,121$11.4M
ROYCE & ASSOCIATES LPADD2,081,579$9.2M
BANK OF AMERICA CORP /DE/ADD1,315,332$5.8M
VANGUARD PORTFOLIO MANAGEMENT LLCTRIM1,141,592$5.1M
HRT FINANCIAL LPDOUBLED997,769$4.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 3 analysts

Price is inside the target range. Median implies +0%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
May 13, 2026Stephens & Co.
MAINTAIN
MAINTAINOverweight
May 12, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight

Insider ledger

Form 4
$0
open-market buys or sells · since May 18
DateInsiderTypeValue
Aug 18, 2026
Yan Ming
CHIEF TECHNOLOGY OFFICER
TAX W/H$6.3K
Aug 18, 2026
Yan Ming
CHIEF TECHNOLOGY OFFICER
EXERCISE14,220 sh
Aug 18, 2026
Yan Ming
CHIEF TECHNOLOGY OFFICER
EXERCISE5,525 sh
Aug 18, 2026
Yan Ming
CHIEF TECHNOLOGY OFFICER
TAX W/H$8.3K
Aug 18, 2026
Yan Ming
CHIEF TECHNOLOGY OFFICER
TAX W/H$16.2K
Aug 18, 2026
Yan Ming
CHIEF TECHNOLOGY OFFICER
EXERCISE6,162 sh
Aug 18, 2026
Yan Ming
CHIEF TECHNOLOGY OFFICER
TAX W/H$7.0K
Aug 18, 2026
Yan Ming
CHIEF TECHNOLOGY OFFICER
EXERCISE7,363 sh

Earnings setup

Estimates
Nov 4
reports in 8 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.02-$0.04–$0.00+0.0%$63.6M
Current FY🔒 Fresh data, subscribers only
Next FY-$0.25-$0.32–-$0.19+0.0%$222.8M

Short side

FINRA· Oct 15, 2026
4,409,745
shares short
-15.4%
vs prior settlement
2.7
days to cover
≈3.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Cytek Biosciences, Inc. announced it will report its Q3 2026 results on November 4, 2026.
PRESS-RELEASE — Impact 1/10
Oct 21, 2026 Earnings
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “
Sep 22, 2026 SEC
In Q2 2026, institutional activity in Cytek Biosciences (CTKB) was sharply mixed: 20 buyers added $21.5M in holdings…
INST-CLUSTER — Impact 4/10
Aug 24, 2026 SEC
Cytek disclosed a jury verdict in a patent infringement case brought by Beckman Coulter. The jury found in Cytek's…
8-K — Impact 7/10
Aug 18, 2026 Insider
Yan Ming surrendered for taxes 1,346 shares
CHIEF TECHNOLOGY OFFICER @ $4.67 ($6.3K)
Aug 18, 2026 Insider
Yan Ming acquired via exercise 14,220 shares
CHIEF TECHNOLOGY OFFICER
Aug 18, 2026 Insider
Yan Ming acquired via exercise 5,525 shares
CHIEF TECHNOLOGY OFFICER
Jun 30, 2026 Inst.
BlackRock, Inc. — TRIM
9,578,643 shares ($42.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
CTKB Q3 2026 Earnings After Market Close — 2026-11-04
Recent
Oct 21, 2026
Earnings
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it…
Sep 23, 2026
Press release
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry…
Sep 1, 2026
Press release
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today…
Aug 21, 2026
Contract
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a…
Aug 5, 2026
Earnings date
CTKB Q2 2026 Earnings After Market Close — 2026-08-05

SecBot reports

8 filings · 0 bullish · 2 bearish · 1 mixed · 5 neutral
All CTKB filing & press-release reports (8)